Filing Analysis
Regulation FD Disclosure
Filed Mar 25, 2026
LOW
Equillium, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. The information was furnished via a press release and does not include any immediate material changes to corporate structure or auditor status.
Key Facts
- Report date: March 25, 2026
- Financial period covered: Fourth quarter and full year ended December 31, 2025
- The filing was made under Item 2.02 (Results of Operations and Financial Condition)
- The report was signed by Bruce D. Steel, Chief Executive Officer
Securities Offering
Filed Mar 13, 2026
MEDIUM
Equillium, Inc. entered into a securities purchase agreement for a private placement (PIPE) with RA Capital Healthcare Fund, L.P., raising approximately $35.0 million in gross proceeds. The transaction involves the sale of common stock and pre-funded warrants to fund the development of its EQ504 program and for general working capital.
Red Flags
- Substantial potential dilution from the issuance of over 17.6 million shares via pre-funded warrants.
- The securities are being sold in an unregistered private placement, bypassing standard public offering scrutiny.
Key Facts
- Total gross proceeds of approximately $35.0 million from RA Capital Healthcare Fund, L.P.
- Issuance of 1,179,508 shares of common stock at $1.854 per share.
- Issuance of pre-funded warrants to purchase up to 17,698,593 shares at $1.8539 per warrant share.
- The purchase price was based on the five-day average closing price prior to the agreement.
- The company is required to file a resale registration statement within 30 days of closing.
- Closing is anticipated on or about March 13, 2026.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.